These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 20814894)

  • 1. Drug therapy: rifaximin.
    Bajaj JS; Riggio O
    Hepatology; 2010 Oct; 52(4):1484-8. PubMed ID: 20814894
    [No Abstract]   [Full Text] [Related]  

  • 2. Rifaximin for the treatment of hepatic encephalopathy.
    Mantry PS; Munsaf S
    Transplant Proc; 2010 Dec; 42(10):4543-7. PubMed ID: 21168733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy - a decision analysis.
    Huang E; Esrailian E; Spiegel BM
    Aliment Pharmacol Ther; 2007 Oct; 26(8):1147-61. PubMed ID: 17894657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy.
    Leevy CB; Phillips JA
    Dig Dis Sci; 2007 Mar; 52(3):737-41. PubMed ID: 17245628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy.
    Sharma BC; Sharma P; Lunia MK; Srivastava S; Goyal R; Sarin SK
    Am J Gastroenterol; 2013 Sep; 108(9):1458-63. PubMed ID: 23877348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is Lactulose Plus Rifaximin Better than Lactulose Alone in the Management of Hepatic Encephalopathy?
    Butt NI; Butt UI; Kakar AATK; Malik T; Siddiqui AM
    J Coll Physicians Surg Pak; 2018 Feb; 28(2):115-117. PubMed ID: 29394969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rifaximin (Xifaxan 550) for hepatic encephalopathy.
    Med Lett Drugs Ther; 2010 Nov; 52(1350):87. PubMed ID: 21045761
    [No Abstract]   [Full Text] [Related]  

  • 8. [Intestine specific broad spectrum antibiotic. Rifaximin: therapy option in hepatic encephalopathy].
    MMW Fortschr Med; 2014 Feb; 156(3):64-5. PubMed ID: 24938070
    [No Abstract]   [Full Text] [Related]  

  • 9. ACP Journal Club. Adding rifaximin to lactulose increased reversal and decreased mortality in hepatic encephalopathy.
    Kowdley KV; Burman BE
    Ann Intern Med; 2013 Oct; 159(8):JC8. PubMed ID: 24126669
    [No Abstract]   [Full Text] [Related]  

  • 10. Analysis of hospitalizations comparing rifaximin versus lactulose in the management of hepatic encephalopathy.
    Neff GW; Kemmer N; Zacharias VC; Kaiser T; Duncan C; McHenry R; Jonas M; Novick D; Williamson C; Hess K; Thomas M; Buell J
    Transplant Proc; 2006 Dec; 38(10):3552-5. PubMed ID: 17175328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rifaximin: an alternative for the treatment of hepatic encephalopathy.
    Rigali VT
    Conn Med; 2006 Sep; 70(8):499-501. PubMed ID: 17089807
    [No Abstract]   [Full Text] [Related]  

  • 12. Rifaximin for episodic, overt hepatic encephalopathy: the data are catching up to clinical practice, but questions remain.
    Congly SE; Leise MD
    Am J Gastroenterol; 2014 Apr; 109(4):598. PubMed ID: 24698864
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy of rifaximin versus lactulose for reducing the recurrence of overt hepatic encephalopathy and hopitalizations in cirrhosis.
    Irimia R; Trifan A
    Rev Med Chir Soc Med Nat Iasi; 2012; 116(4):1021-7. PubMed ID: 23700882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Durability of rifaximin response in hepatic encephalopathy.
    Neff GW; Jones M; Broda T; Jonas M; Ravi R; Novick D; Kaiser TE; Kemmer N
    J Clin Gastroenterol; 2012 Feb; 46(2):168-71. PubMed ID: 22011586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of hepatic encephalopathy with rifaximin: more to think about.
    Gitlin N
    Hepatology; 2011 Mar; 53(3):1059; author reply 1059-60. PubMed ID: 21294145
    [No Abstract]   [Full Text] [Related]  

  • 16. Factors affecting compliance and persistence with treatment for hepatic encephalopathy.
    Neff G
    Pharmacotherapy; 2010 May; 30(5 Pt 2):22S-7S. PubMed ID: 20412037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rifaximin, a nonabsorbed oral antibiotic, in the treatment of hepatic encephalopathy: antimicrobial activity, efficacy, and safety.
    Williams R; Bass N
    Rev Gastroenterol Disord; 2005; 5 Suppl 1():S10-8. PubMed ID: 15976747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapy for the treatment and prevention of hepatic encephalopathy.
    Mohammad RA; Regal RE; Alaniz C
    Ann Pharmacother; 2012 Nov; 46(11):1559-63. PubMed ID: 23092866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study.
    Paik YH; Lee KS; Han KH; Song KH; Kim MH; Moon BS; Ahn SH; Lee SJ; Park HJ; Lee DK; Chon CY; Lee SI; Moon YM
    Yonsei Med J; 2005 Jun; 46(3):399-407. PubMed ID: 15988813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pay more attention to hepatic encephalopathy].
    Labenz J
    MMW Fortschr Med; 2014 Feb; 156(2):60-1. PubMed ID: 24934059
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.